In March 2025, the European Medicines Agency (EMA) introduced a comprehensive three-year work plan for the Good Manufacturing and Distribution Practice (GMDP) Inspectors Working Group (IWG), outlining their objectives for 2025–2027. The plan underscored the significance of supply chain integrity, product quality, and the influence of emerging manufacturing technologies on the supply chain. Notably, the plan aimed to enhance the regulatory landscape to ensure the safety and efficacy of pharmaceutical products. Central to this initiative were goals such as bolstering supply chain resilience, ensuring product quality, and incorporating new manufacturing technologies effectively.
A pivotal development occurred on July 7, 2025, when the GMDP-Inspectors Working Group, in collaboration with the Pharmaceutical Inspection Co-operation Scheme (PIC/S), commenced a public consultation concerning the revision of the European Union’s good manufacturing practice (GMP) guidelines, specifically focusing on EudraLex Annex 11 and Chapter 4. Additionally, a new Annex 22 dedicated to artificial intelligence (AI) was introduced to set guidelines for the regulated use of AI and machine learning in GMP environments. These revisions and additions aimed to expand documentation requirements, enhance digital system validation processes, and establish clear boundaries for utilizing AI and ML in pharmaceutical manufacturing to ensure regulatory alignment across the industry.
The revised Chapter 4 emphasized the pivotal role of documentation in GMP compliance and endorsed the adoption of innovative technologies and hybrid solutions for documentation management. Risk-management principles were integrated into the data governance system to uphold the accuracy, integrity, and availability of documents in all formats throughout their lifecycle. Furthermore, the guidelines addressed electronic record management, data integrity, and aligned with the updated Annex 11 to streamline documentation practices and ensure compliance with evolving regulatory standards.
Annex 11 underwent significant enhancements to oversee computerized systems throughout their lifecycle, emphasizing the application of quality risk management principles at all stages to safeguard product quality, patient safety, and data integrity. The revised provisions mandated stringent adherence to defining system requirements, monitoring suppliers and service providers, and strengthening controls for data integrity, audit trails, electronic signatures, system security, and data backup processes. These changes were pivotal in ensuring robust system governance and compliance with GMP standards.
The introduction of Annex 22 provided specific guidelines for incorporating AI/ML technologies in manufacturing active substances and medicinal products, outlining requirements for model selection, training, validation, and performance evaluation. It emphasized the importance of defining model usage, establishing performance metrics, ensuring data quality, and implementing robust oversight mechanisms for AI systems. Notably, the annex excluded generative AI and large language models from critical GMP applications, emphasizing the need for stringent controls and oversight in utilizing AI technologies in pharmaceutical manufacturing.
The updates to Chapter 4, Annex 11, and the addition of Annex 22 marked a significant shift in European GMP regulations for the pharmaceutical industry, necessitating pharmaceutical companies to reassess their documentation processes, validate legacy systems, and enhance system governance to comply with the updated requirements. Companies deploying AI technologies in GMP environments must develop internal capabilities to ensure data governance and validate AI models effectively, aligning with the evolving regulatory landscape. Stakeholders have until October 7, 2025, to provide feedback on the proposed revisions, shaping the future of GMP compliance in Europe.
- Pharmaceutical companies need to review and validate their documentation processes and legacy systems to comply with updated GMP requirements.
- Organizations deploying AI technologies must develop robust internal capabilities for data governance and AI model validation.
- The stakeholder consultation deadline for feedback on the revised GMP guidelines is October 7, 2025.
Tags: regulatory, radiopharmaceuticals, quality control
Read more on pharmtech.com